Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on McKesson (MCK – Research Report), Biogen (BIIB – ...
Gilead Sciences CFO Andrew Dickinson sells $14 million in stock
Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Zacks.com on MSN20h
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...